site search by freefind

Updated: Nov 15, 2020

    Do you know someone with COVID-19?
    We're now looking for currently or recently ill COVID-19 patients to volunteer to test our non-drug, psycho-immunology approach to treating the disease. (The informed consent and liability form in English can be downloaded from here; in French; in German; in Spanish; in Polish; in Russian.) If you are interested in participating, please contact our medical director Mary Pellicer MD by phoning +1-‭509-965-4502‬ or clicking on the contact button below:

A psycho-immunology approach
For readers who are not familiar with psycho-immunology, it has several unique features. Theoretically, a treatment using this approach should allow us to both (1) eliminate any of the symptoms (and pathogens) currently in an infected person, as well as (2) make people immune to getting the disease in the future. The most important feature is that symptom relief is immediate and occurs in the office during treatment, allowing one to have immediate confidence in the technique. This webpage explains psycho-immunology in more detail.

But to develop a treatment, we first need people with the actual disease who are willing to be involved in the long, difficult investigative phase. From a research perspective, we were very fortunate in that one of our research staff contracted COVID-19 (based on matching symptoms) early in the pandemic, allowing us on March 4 2020 to start investigating the disease using our new, third-generation psycho-immunological approach. As of this writing, we've tested our preliminary treatment on a total of three infected symptomatic patients (N=3).
Coronavirus ameboid goo

Amebic Carriers
To our great surprise, so far we haven't seen the coronavirus directly infecting humans. Instead, we see two different carriers for the coronavirus. Both appear to be ameba (both have a nucleus) and feel 'gooey' to the regressed patient. Each species infects the person quite differently:
  • Airborne ameba: This pathogen floats in the air for a time after an infected person breathes them out. We cannot be sure without electrical engineering equipment, but it appears to stay airborne for a time by using an electrostatic field. If so, this suggests that (1) an infected person could be identified by using cheap sensitive electrostatic detectors, and (2) it might be possible to 'drag' the pathogen out of the air by using an electrostatic field, again a cheap and readily purchased item.
  • Touch ameba: This pathogen sticks to the skin, and is passed to another person through skin contact (for example, by shaking another person's hand). It is also likely that this ameba would stick to and survive on other surfaces for a time, but we were not able to test this.

After being carried into the body via the ameba, the virus infects cells in the body. In our small sample size (N=3), so far we've only seen the virus in tissue of the lower lungs.

This virus (and other viruses in our limited experience) is also associated with a psychological issue that could be summed up with the phrase 'I don't give a shit', along with a strong resistance to letting go of the target virus. This appears to be both a generational issue; as well as involving an active bacterial infection (prenatally acquired) that also carried a viral payload.

This tri-pathogen model would suggest a roughly similar global distributions of pandemic virulence, which does not appear to be the case. Thus, we continue to look for possible co-factors, such as environmental toxicity or other pathogens.

Testing and validation
Given that there are at least three infectious pathogens to COVID-19, we derived a separate, simple treatment for each pathogen type. To our surprise, first treating only the viral load in a very sick patient did not immediately eliminate their symptoms. However, first treating only the touch ameba in another patient (which was the dominant pathogen in this person) immediately got rid of their major symptoms of breathing difficulty, exhaustion, and inability to sleep. Thus, it appears their major symptoms were due to their amebic load and not directly due to the virus.

Phase 1: On May 3 2020 we started testing our psycho-immunology treatments in a healthy test group to look for any potential side-effects and to estimate treatment times. Testing ended May 17. Fortunately, we did not encounter any safety issues or side effects, either in the group that was unsuccessful in using the process, or in the group that was successful. (Success was defined as the occurrence of a distinct kinesthetic experience in the volunteer that indicates the process was finished.) Our results were:
  • Airborne ameba: success rate = 65%; treatment time = 89 minutes with SD = 42 minutes; N = 23.
  • Touch ameba: success rate = 84%, treatment time = 58 minutes with SD = 26 minutes, N = 19.
  • Virus: success rate = 76%, treatment time = 80 minutes with SD = 53 minutes, N = 21.
We did have one very unexpected result. Three of the test cases (N=3) had previously recovered from COVID-19, and had been without symptoms for several weeks before the test started. However, when we used the viral treatment step on them, within a minute or two of starting the treatment all three found that their symptoms immediately came back, and were even more severe than when they had been sick (in their self-report). By continuing the treatment, all their COVID-19 symptoms vanished, and in fact when they were finished the test treatment they all reported they lost subclinical residual COVID-19 symptoms that they had not even been aware of until they went away. The implications of this observation is disturbing - it suggests that people do not get natural immunity to coronavirus as we have all been assuming, but instead it goes into remission and stays in the body. Clearly, more research is required to find out if this is the case or not.

On May 27 2020, we started working on a simpler and more effective process (rev 3.0) to eliminate all three pathogens simultaneously; and on June 7, we tested it on 16 healthy volunteers. The testing revealed no safety issues or side-effects.
  • New single treatment protocol: success rate: 82%; treatment time = 41 minutes with SD = 13 minutes; N = 17.

Phase 1b: On June 12, 2020, we tested this new process on an athlete volunteer recovering from COVID-19 who still had some post-infection breathing difficulty. Our new process simultaneously eliminated both ameba types and the virus in the patient, and returned their breathing to normal. This matched our model. Obviously, this is only one case, and we will now wait to see that the changes are stable.

June 20, 2020: We are now beginning testing on currently symptomatic and post-recovery volunteers. If you have or had COVID-19 and are interested in participating in these tests, contact us by clicking on the contact button at the top of this webpage.

Sept 26, 2020: Testing revision 3.0 treatment on two hospitalized patients did not eliminate their symptoms - yet the treatment worked successfully on our post-covid patients. We eventually identified another pathogen, a bacteria attached to the outside of the amebic carriers of the virus, that was contributing to symptoms and symptom retention. We also identified a prion-like infection held in the core of the coronavirus which was released when the viral coating was dissolved.

Thus, this difference between post-covid and active cases results was due to the presence of the non-viral pathogens in the active cases - the post-covid patients' immune systems had eliminated these non-viral pathogens, leaving only the virus. We redesigned the treatment to revision 4.0 to also eliminate all of the initial infection pathogens as well as the virus. Testing on one active patient (N=1) immediately eliminated all their covid symptoms.

Nov 15, 2020: Our rev 4.1 treatment worked very well on our last two seriously ill patients, relieving symptoms immediately at the end of the treatment session. Also, we are now seeing that our current patients have different, slightly mutated forms of the coronavirus; fortunately, the rev 4.x approach automatically covers the current range of viral strains (mutations) that we've encountered so far.

We continue to look for more patients with active symptoms to test this treatment revision.

Suggested Reading
  • "Using Psycho-immunology for COVID-19", PeakStates newsletter #19, Aug 3, 2020.
  • "Editorial: Amoebae as Host Models to Study the Interaction With Pathogens", Frontiers in Cellular and Infection Microbiology, March 19, 2019.
  • "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science magazine, April 17, 2020.
  • "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1", New England Journal of Medicine, April 16, 2020.
  • "Epigentics, psychoneuroimmunology, and subcellular psychobiology", PeakStates research blog, May 3, 2016.
  • "How long does the coronavirus last inside the body?", National Geographic, June 3, 2020.
  • "Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients", Lednicky et al., MedRxiv Aug 3, 2020. "A Smoking Gun’: Infectious Coronavirus Retrieved From Hospital Air", New York Times Aug 11, 2020.
  • "Scientists Uncover Biological Signatures of the Worst Covid-19 Cases", The New York Times, Aug 5, 2020; "Researchers find three distinct immune responses for sicker COVID-19 patients", Medical XPress, July 15, 2020; Longitudinal analyses reveal immunological misfiring in severe COVID-19", Nature, July 27, 2020.

Revision History
Nov 15, 2020: Reported initial successful results for the rev 4.1 technique. We are now seeing different coronavirus strains.
Sept 26, 2020: Updated with preliminary results from active COVID-19 patients. We note there is initially a bacterial component to COVID.
Aug 2, 2020: Added the Phase 1b effectiveness trial disclosure and liability PDF.
June 20, 2020: Start testing of COVID-19 volunteers.
June 16: Added the results of an improved process test.
May 29, 2020: Added the first psycho-immunology process test results.
May 4, 2020: First webpage on our coronavirus psycho-immunology research and treatment.

...or visit our Forum